EPA:TNG - Euronext Paris - Matif - FR0005175080 - Common Stock - Currency: EUR
EPA:TNG (5/13/2025, 7:00:00 PM)
0.59
0 (-0.34%)
The current stock price of TNG.PA is 0.59 EUR. In the past month the price decreased by -7.48%. In the past year, price decreased by -55.2%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.16 | 297.19B | ||
AMG.DE | AMGEN INC | 13.18 | 132.40B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.27 | 115.15B | ||
GIS.DE | GILEAD SCIENCES INC | 13.04 | 113.13B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 100.62B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 11.72 | 52.64B | ||
ARGX.BR | ARGENX SE | 101.39 | 29.84B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.77B | ||
IDP.DE | BIOGEN INC | 7.79 | 16.26B | ||
1MRNA.MI | MODERNA INC | N/A | 8.90B | ||
0QF.DE | MODERNA INC | N/A | 8.86B | ||
BIO.DE | BIOTEST AG | 65.54 | 1.69B |
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 158 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
TRANSGENE SA
400 Boulevard Gonthier d'Andernach, Parc d'Innovation - CS80166, Cedex
Illkirch-Graffenstaden GRAND EST FR
Employees: 144
Phone: 33388279100
The current stock price of TNG.PA is 0.59 EUR. The price decreased by -0.34% in the last trading session.
The exchange symbol of TRANSGENE SA is TNG and it is listed on the Euronext Paris - Matif exchange.
TNG.PA stock is listed on the Euronext Paris - Matif exchange.
7 analysts have analysed TNG.PA and the average price target is 1.73 EUR. This implies a price increase of 193.9% is expected in the next year compared to the current price of 0.59. Check the TRANSGENE SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TRANSGENE SA (TNG.PA) has a market capitalization of 78.05M EUR. This makes TNG.PA a Micro Cap stock.
TRANSGENE SA (TNG.PA) currently has 144 employees.
TRANSGENE SA (TNG.PA) has a resistance level at 0.61. Check the full technical report for a detailed analysis of TNG.PA support and resistance levels.
The Revenue of TRANSGENE SA (TNG.PA) is expected to decline by -44.69% in the next year. Check the estimates tab for more information on the TNG.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TNG.PA does not pay a dividend.
TRANSGENE SA (TNG.PA) will report earnings on 2025-09-16.
TRANSGENE SA (TNG.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
ChartMill assigns a fundamental rating of 2 / 10 to TNG.PA. Both the profitability and financial health of TNG.PA have multiple concerns.
Over the last trailing twelve months TNG.PA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 32.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -43.99% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to TNG.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 28% and a revenue growth -44.69% for TNG.PA